HOENIGL, Martin, Jon SALMANTON-GARCÍA, Matthias EGGER, Gangneux JEAN-PIERRE, Tihana BICANIC, Sevtap ARIKAN-AKDAGLI, Ana ALASTRUEY-IZQUIERDO, Nikolai KLIMKO, Aleksandra BARAC, Volkan ÖZENCI, Eelco F J MEIJER, Nina KHANNA, Matteo BASSETTI, Riina RAUTEMAA-RICHARDSON, Katrien LAGROU, Adam KAI-MANUEL, Emin Halis AKALIN, Murat AKOVA, Valentina Arsic ARSENIJEVIC, Avinash AUJAYEB, Ola BLENNOW, Stéphane BRETAGNE, François DANION, Blandine DENIS, Nick Alexander de JONGE, Guillaume DESOUBEAUX, Lubos DRGONA, Nurettin ERBEN, Andrea GORI, Julio García RODRÍGUEZ, Carolina GARCIA-VIDAL, Daniele Roberto GIACOBBE, Anna L GOODMAN, Petr HAMAL, Helena HAMMARSTRÖM, Cristina TOSCANO, Fanny LANTERNIER, Cornelia LASS-FLÖRL, Deborah E A LOCKHART, Thomas LONGVAL, Laura LOUGHLIN, Tadeja MATOS, Malgorzata MIKULSKA, Manjusha NARAYANAN, Sonia MARTÍN-PÉREZ, Juergen PRATTES, Benedict ROGERS, Laman RAHIMLI, Maite RUIZ, Emmanuel ROILIDES, Michael SAMARKOS, Ulrike SCHARMANN, Uluhan SILI, Oguz Resat SIPAHI, Alena SIVÁKOVÁ, Joerg STEINMANN, Janina TRAUTH, Ozge TURHAN, Jens Van PRAET, Antonio VENA, P Lewis WHITE, Birgit WILLINGER, Anna Maria TORTORANO, Maiken C ARENDRUP, Philipp KOEHLER a Oliver A CORNELY. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. The Lancet Infectious Diseases. OXFORD: ELSEVIER SCI LTD, 2023, roč. 23, č. 6, s. 751-761. ISSN 1473-3099. Dostupné z: https://dx.doi.org/10.1016/S1473-3099(22)00872-6.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
Autoři HOENIGL, Martin (garant), Jon SALMANTON-GARCÍA, Matthias EGGER, Gangneux JEAN-PIERRE, Tihana BICANIC, Sevtap ARIKAN-AKDAGLI, Ana ALASTRUEY-IZQUIERDO, Nikolai KLIMKO, Aleksandra BARAC, Volkan ÖZENCI, Eelco F J MEIJER, Nina KHANNA, Matteo BASSETTI, Riina RAUTEMAA-RICHARDSON, Katrien LAGROU, Adam KAI-MANUEL, Emin Halis AKALIN, Murat AKOVA, Valentina Arsic ARSENIJEVIC, Avinash AUJAYEB, Ola BLENNOW, Stéphane BRETAGNE, François DANION, Blandine DENIS, Nick Alexander de JONGE, Guillaume DESOUBEAUX, Lubos DRGONA, Nurettin ERBEN, Andrea GORI, Julio García RODRÍGUEZ, Carolina GARCIA-VIDAL, Daniele Roberto GIACOBBE, Anna L GOODMAN, Petr HAMAL, Helena HAMMARSTRÖM, Cristina TOSCANO, Fanny LANTERNIER, Cornelia LASS-FLÖRL, Deborah E A LOCKHART, Thomas LONGVAL, Laura LOUGHLIN, Tadeja MATOS, Malgorzata MIKULSKA, Manjusha NARAYANAN, Sonia MARTÍN-PÉREZ, Juergen PRATTES, Benedict ROGERS, Laman RAHIMLI, Maite RUIZ, Emmanuel ROILIDES, Michael SAMARKOS, Ulrike SCHARMANN, Uluhan SILI, Oguz Resat SIPAHI, Alena SIVÁKOVÁ (203 Česká republika, domácí), Joerg STEINMANN, Janina TRAUTH, Ozge TURHAN, Jens Van PRAET, Antonio VENA, P Lewis WHITE, Birgit WILLINGER, Anna Maria TORTORANO, Maiken C ARENDRUP, Philipp KOEHLER a Oliver A CORNELY.
Vydání The Lancet Infectious Diseases, OXFORD, ELSEVIER SCI LTD, 2023, 1473-3099.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30303 Infectious Diseases
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 56.300 v roce 2022
Kód RIV RIV/00216224:14110/23:00130480
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/S1473-3099(22)00872-6
UT WoS 001023025000001
Klíčová slova anglicky candidaemia; Europe
Štítky 14110113, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 25. 1. 2024 15:59.
Anotace
Background The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is associated with outcomes. Methods In this observational cohort study, 64 participating hospitals located in 20 European countries, with the number of eligible hospitals per country determined by population size, included the first ten consecutive adults with culture-proven candidaemia after July 1, 2018, and entered data into the ECMM Candida Registry (FungiScope CandiReg). We assessed ECMM Quality of Clinical Candidaemia Management (EQUAL Candida) scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of America guidelines. Findings 632 patients with candidaemia were included from 64 institutions. Overall 90-day mortality was 43% (265/617), and increasing age, intensive care unit admission, point increases in the Charlson comorbidity index score, and Candida tropicalis as causative pathogen were independent baseline predictors of mortality in Cox regression analysis. EQUAL Candida score remained an independent predictor of mortality in the multivariable Cox regression analyses after adjusting for the baseline predictors, even after restricting the analysis to patients who survived for more than 7 days after diagnosis (adjusted hazard ratio 1·08 [95% CI 1·04–1·11; p<0·0001] in patients with a central venous catheter and 1·09 [1·05–1·13; p<0·0001] in those without one, per one score point decrease). Median duration of hospital stay was 15 days (IQR 4–30) after diagnosis of candidaemia and was extended specifically for completion of parenteral therapy in 100 (16%) of 621 patients. Initial echinocandin treatment was associated with lower overall mortality and longer duration of hospital stay among survivors than treatment with other antifungals. Interpretation Although overall mortality in patients with candidaemia was high, our study indicates that adherence to clinical guideline recommendations, reflected by higher EQUAL Candida scores, might increase survival. New antifungals, with similar activity as current echinocandins but with longer half-lives or oral bioavailability, are needed to reduce duration of hospital stay.
VytisknoutZobrazeno: 3. 9. 2024 06:07